Posted by Michael Wonder on 17 Feb 2021
Health Canada approves Reblozyl (luspatercept), new class of treatment for adult patients living with myelodysplastic syndromes
16 February 2021 - Reblozyl, an erythroid maturation agent, is the first and only of its kind approved for use in Canada.
BMS and Acceleron Pharma announced today that Health Canada has approved Reblozyl (luspatercept for injection) for the treatment of adult patients with transfusion-dependent anaemia requiring at least two red blood cell units over 8 weeks resulting from very low-to intermediate-risk myelodysplastic syndromes who have ring sideroblasts and who have failed or are not suitable for erythropoietin-based therapy.
